In vitro functional characterization of biosimilar therapeutic antibodies

Q1 Pharmacology, Toxicology and Pharmaceutics Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI:10.1016/j.ddtec.2020.11.010
Júlia Anna Láng, Zsófia Cselovszkiné Balogh, Mónika Fizilné Nyitrai, Cintia Juhász, Anna Katalin Baráné Gilicze, Attila Iliás, Zsolt Zólyomi, Csaba Bodor, Erzsébet Rábai
{"title":"In vitro functional characterization of biosimilar therapeutic antibodies","authors":"Júlia Anna Láng,&nbsp;Zsófia Cselovszkiné Balogh,&nbsp;Mónika Fizilné Nyitrai,&nbsp;Cintia Juhász,&nbsp;Anna Katalin Baráné Gilicze,&nbsp;Attila Iliás,&nbsp;Zsolt Zólyomi,&nbsp;Csaba Bodor,&nbsp;Erzsébet Rábai","doi":"10.1016/j.ddtec.2020.11.010","DOIUrl":null,"url":null,"abstract":"<div><p><span>The key factor in successful development and marketing of biosimilar antibodies is a deep understanding of their critical quality attributes and the ability to control them. Comprehensive functional characterization is therefore at the heart of the process and is a crucial part of regulatory requirements. Establishment of a scientifically sound molecule-specific functional </span><em>in vitro</em> assay panel requires diligent planning and high flexibility in order to respond to both regulatory requirements and the ever-changing demands relevant to the different stages of the development and production process. Relevance of the chosen assays to the <em>in vivo</em> mechanism of action is of key importance to the stepwise evidence-based demonstration of biosimilarity. Use of a sound interdisciplinary approach and orthogonal state-of-the-art techniques is also unavoidable for gaining in-depth understanding of the biosimilar candidate.</p><p>The aim of the present review is to give a snapshot on the methodic landscape as depicted by the available literature discussing the <em>in vitro</em><span> techniques used for the functional characterization of approved biosimilar therapeutic antibodies. Emerging hot topics of the field and relevant structure-function relationships are also highlighted.</span></p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2020.11.010","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Technologies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740674920300317","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 6

Abstract

The key factor in successful development and marketing of biosimilar antibodies is a deep understanding of their critical quality attributes and the ability to control them. Comprehensive functional characterization is therefore at the heart of the process and is a crucial part of regulatory requirements. Establishment of a scientifically sound molecule-specific functional in vitro assay panel requires diligent planning and high flexibility in order to respond to both regulatory requirements and the ever-changing demands relevant to the different stages of the development and production process. Relevance of the chosen assays to the in vivo mechanism of action is of key importance to the stepwise evidence-based demonstration of biosimilarity. Use of a sound interdisciplinary approach and orthogonal state-of-the-art techniques is also unavoidable for gaining in-depth understanding of the biosimilar candidate.

The aim of the present review is to give a snapshot on the methodic landscape as depicted by the available literature discussing the in vitro techniques used for the functional characterization of approved biosimilar therapeutic antibodies. Emerging hot topics of the field and relevant structure-function relationships are also highlighted.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生物类似药治疗性抗体的体外功能表征
成功开发和销售生物仿制药抗体的关键因素是对其关键质量属性的深刻理解和控制能力。因此,全面的功能表征是该过程的核心,也是监管要求的关键部分。建立一个科学合理的分子特异性功能体外检测小组需要勤奋的规划和高度的灵活性,以响应监管要求和与开发和生产过程的不同阶段相关的不断变化的需求。所选择的检测方法与体内作用机制的相关性对于逐步证明生物相似性至关重要。为了深入了解候选生物仿制药,使用合理的跨学科方法和正交的最新技术也是不可避免的。本综述的目的是通过现有文献讨论用于已批准的生物类似药治疗性抗体功能表征的体外技术,对方法景观进行概述。重点介绍了该领域的新兴热点和相关的结构-功能关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discovery Today: Technologies
Drug Discovery Today: Technologies Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
自引率
0.00%
发文量
0
期刊介绍: Discovery Today: Technologies compares different technological tools and techniques used from the discovery of new drug targets through to the launch of new medicines.
期刊最新文献
Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches Application of proteomic data in the translation of in vitro observations to associated clinical outcomes Advances in sample preparation for membrane proteome quantification Application of proteomics to understand maturation of drug metabolizing enzymes and transporters for the optimization of pediatric drug therapy Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1